LiveSpo® Navax probiotics that contain Bacillus spores effectively support symptomatic treatment and reduce the concentration of respiratory syncytial virus (RSV) in children
##plugins.themes.vojs.article.main##
Abstract
Background/Aims: Infection with the Respiratory Syncytial Virus (RSV) is one of the most common causes of respiratory tract diseases. This study was conducted to initially investigate supportive therapeutic effects of probiotic product LiveSpo® Navax, as liquid form containing Bacilus spores of LS-III generation at a high concentration, in children having acute respiratory diseases caused by RSV at the Vietnam National Children’s Hospital. Methods: Totally 30 patients acquiring bronchiolitis
participated in the blind clinical study. The patients were divided randomly into 2 groups (n = 15/group each): one using LiveSpo® Navax (Navax group) and the other using 0.9% NaCl physiological saline (Control group), and were instructed to perform nasal spraying at frequency of 3 times per day for continuous 6 days, in combination with conventional drug therapy in the hospital. The patients were monitored their clinical indicators throughout the treatment period and underwent tests such
as: (i) RSV rapid test at day 0, quantitative analysis of RSV, B. subtilis and B. clausii concentrations in nasal wash sample at day 0 and day 3 by real-time PCR. Results: The Navax group had about 1-day shorter recovery time of symptoms such as nasal secretion, dificutly breathing, sonorous rales, moist rales, chest depression than the control group. After 3 days of treatment, the Navax group had about 300-fold reduced RSV concentration in their nasal fluid, while the control group had only 15-fold
reduction; in association with the presence of B. subtilis and B. clausii in the nasal fluids of Navax group but absence in Control group. 100% of patients using LiveSpo® Navax showed neither signs of abnormal breath, pulse, irritation of the nasal mucosa, nor digestion. Conclusion: This study is the first clinical trial in chidren in the world to demonstrate safety and effects of Bacillus spore probiotics as nasal spray. LiveSpo® Navax provided 1-day earlier treatment time of typtical symptoms for respiratory diseases caused by RSV infection, as well as effectively reduced the concentration of RSV in nasal fluid of children by 20-fold higher than 0.9% NaCl physiological saline.
##plugins.themes.vojs.article.details##
References
2. Pierce R, Giuliano J, Lakhani S. Overview RSV (Respiratory Syncytial Virus) - Fact Sheets. Yale Medicine, 2021.
3. CDC report (Respiratory Syncytial Virus): People at high risk for RSV, 2020.
4. Gia tăng bệnh nhi mắc virus hợp bào hô hấp: Khuyến cáo khẩn từ chuyên gia Bệnh viện Nhi Trung ương. Sức khỏe và đời sống, 2020. Bộ Y tế.
5. Isolauri E, Sütas Y, Kankaanp P et al. Probiotics: Effects on immunity. The American Journal of Clinical Nutrition. 2001; 73, 444S-450S.
6. Kassa AI. New Insights on Antiviral Probiotics: From Research to Applications, 1st Ed., Kindle Edition, Springer, 2017.
7. LehtoRalta L, PitkäRalta A, Korpela R. Probiotics in respiratory virus infections. European Journal of Clinical Microbiology & Infectious Diseases. 2014; 33(8), 1289–1302. doi:10.1007/s10096-014-2086.
8. Sadeghi A, Ali Mortazavi S, Reza Bahrami A et al. Designing a SYBR Green Absolute Real time PCR Assay for Specific Detection and Quantification of Bacillus subtilis in Dough Used for Bread Making. Journal of Cell and Molecular Research. 2014; 6:83–92.
9. Perotti M, Mancini N, Cavallero A et al. Quantitation of Bacillus clausii in biological samles by real-times polymerase chain reaction. Journal
of Microbiology Method. 2006; 65:632-636. https://doi.org/10.1016/j.mimet.2005.10.010.
10. Chiba E, Tomosada Y, Guadalupe MVP et al. Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection. International Immunopharmacology. 2013; 17:373–382. https://doi.org/10.1016/j.intimp.2013.06.024.
11. Eguchi K, Fujitani N, Nakagawa H et al. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus
gasseri SBT2055. Scientific Reports. 2019;9(1). https://doi:10.1038/s41598-019-39602-7.
12. Wang X, Hu W, Zhu L, Yang Q. Bacillus subtilis and surfactin inhibit the transmissible gastroenteritis virus entering intestinal epithelial
cells. Bioscience Reports. 2017; 37: BSR20170082. doi: https://doi.org/10.1042/BSR20170082.